Sign in
TerminatedPhase 4

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

Key facts

Who runs it
Penn State University
Where
University Park, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 4
People taking part
6 people enrolled
Started
1 May 2018
Ended
31 Aug 2024
Type of study
Interventional
Treatments tested
  • Atorvastatin
Record updated
30 January 2025
Why it stopped
COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician <5 years prior, and reported by the subject to the researchers)

Who cannot take part

  • Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
  • Taking illicit and/or recreational drugs
  • Rash, skin disease, disorders of pigmentation, known skin allergies
  • Diagnosed or suspected metabolic or cardiovascular disease
  • Known allergy to latex or investigative substances
  • Diabetes (HbA1C .6.5%)
  • Persistent unexplained elevations of serum transaminases
  • Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
  • BP>140/90
  • Pregnancy
  • Breastfeeding
  • Abnormal liver function

Where in United States

  • The Pennsylvania State UniversityUniversity Park, United States

About the trial

What the trial wants to find out

Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb. This disorder impairs the function of the cells that line the body's blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder have an increased risk for high blood pressure and high cholesterol. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease.

The group in the trial

  • AtorvastatinTreatment being tested

    Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days. Atorvastatin acts as a systemic LOX inhibitor.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 January 2025